Signal
GSK is paying $2.2 billion to buy Rapt Therapeutics and its anti-immunoglobulin E (IgE) antibody to protect against food allergy reactions.
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-01-20 10:08 UTCUpdated 2026-01-20 18:00 UTC
rssx
fierce_biotech
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines businesses.
Score total
1.32
Momentum 24h
3
Posts
3
Origins
2
Source types
2
Duplicate ratio
33%
All evidence
All evidence
GSK is paying $2.2 billion to buy Rapt Therapeutics and its anti-immunoglobulin E (IgE) antibody to protect against food allergy reactions.
Fierce Biotech (All) · fiercebiotech.com · 2026-01-20 18:00 UTC
GSK to buy Rapt in $2.2B deal for food allergy drug
BioPharma Dive (Latest) · biopharmadive.com · 2026-01-20 15:57 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (All) (1)
- BioPharma Dive (Latest) (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- biopharmadive.com (1)